Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts.

Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30563-5. doi: 10.1016/j.jtho.2019.07.006. [Epub ahead of print]

PMID:
31349062
2.

KIT-dependent and -independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Mariño-Enríquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Jul 15. pii: molcanther.1224.2018. doi: 10.1158/1535-7163.MCT-18-1224. [Epub ahead of print]

PMID:
31308077
3.

Optimizing panel-based tumor mutational burden (TMB) measurement.

Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A.

Ann Oncol. 2019 Jul 3. pii: mdz205. doi: 10.1093/annonc/mdz205. [Epub ahead of print]

PMID:
31268125
4.

Defining molecular risk in ALK+ NSCLC.

Christopoulos P, Budczies J, Kirchner M, Dietz S, Sültmann H, Thomas M, Stenzinger A.

Oncotarget. 2019 May 3;10(33):3093-3103. doi: 10.18632/oncotarget.26886. eCollection 2019 May 3.

5.

[From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]

Leichsenring J, Kazdal D, Ploeger C, Allgäuer M, Endris V, Volckmar AL, Neumann O, Kirchner M, Penzel R, Rempel E, Budczies J, Schirmacher P, Fröhling S, Stenzinger A.

Pathologe. 2019 May;40(3):235-242. doi: 10.1007/s00292-019-0608-1. German.

PMID:
31089797
6.

Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.

Pfarr N, Allgäuer M, Steiger K, Weichert W, Schirmacher P, Noske A, Stenzinger A.

Pathology. 2019 Jun;51(4):362-368. doi: 10.1016/j.pathol.2019.01.010. Epub 2019 Apr 19.

PMID:
31010589
7.

Variant classification in precision oncology.

Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A.

Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32358. [Epub ahead of print]

PMID:
31008532
8.

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.

Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C.

Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.

PMID:
30979740
9.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.

Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.

Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.

10.

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.

Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, Kirchner M, Allgäuer M, Schirmacher P, Krämer A, Stenzinger A.

Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32316. [Epub ahead of print]

PMID:
30963573
11.

RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours.

Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A.

Gut. 2019 Jul;68(7):1287-1296. doi: 10.1136/gutjnl-2018-317632. Epub 2019 Feb 2.

PMID:
30901310
12.

Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.

Dieffenbacher S, Nyarangi-Dix J, Giganti F, Bonekamp D, Kesch C, Müller-Wolf MB, Schütz V, Gasch C, Hatiboglu G, Hauffe M, Stenzinger A, Duensing S, Schlemmer HP, Moore CM, Hohenfellner M, Radtke JP.

Eur Urol Focus. 2019 Mar 13. pii: S2405-4569(19)30076-8. doi: 10.1016/j.euf.2019.03.001. [Epub ahead of print]

PMID:
30878348
13.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.

14.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Apr;65(4):549-558. doi: 10.1373/clinchem.2018.296814. Epub 2019 Feb 8.

PMID:
30737205
15.

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.

Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A.

Cancers (Basel). 2019 Jan 21;11(1). pii: E124. doi: 10.3390/cancers11010124.

16.

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.

Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, Dietel M.

Genes Chromosomes Cancer. 2019 Aug;58(8):578-588. doi: 10.1002/gcc.22733. Epub 2019 Mar 7.

17.

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.

Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A.

Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19.

PMID:
30653256
18.

[Spindle and giant cell type undifferentiated carcinoma of the distal bile duct: a case report].

Albrecht T, Mehrabi A, Strobel O, Vogel MN, Stenzinger A, Bergmann F, Schirmacher P, Goeppert B.

Z Gastroenterol. 2019 Jan;57(1):52-56. doi: 10.1055/a-0784-8763. Epub 2019 Jan 14. German.

PMID:
30641603
19.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.

PMID:
30624547
20.

Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.

Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S.

Hepatology. 2019 May;69(5):2091-2106. doi: 10.1002/hep.30493. Epub 2019 Feb 28.

21.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C.

Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018.

PMID:
30524909
22.

Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations.

Kazdal D, Harms A, Endris V, Penzel R, Oliveira C, Kriegsmann M, Longuespée R, Winter H, Schneider MA, Muley T, Pfarr N, Weichert W, Stenzinger A, Warth A.

Lung Cancer. 2018 Dec;126:80-88. doi: 10.1016/j.lungcan.2018.10.024. Epub 2018 Oct 29.

PMID:
30527196
23.

Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A.

Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Review.

24.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.

Nyarangi-Dix J, Wiesenfarth M, Bonekamp D, Hitthaler B, Schütz V, Dieffenbacher S, Mueller-Wolf M, Roth W, Stenzinger A, Duensing S, Roethke M, Teber D, Schlemmer HP, Hohenfellner M, Radtke JP.

Eur Urol Focus. 2018 Nov 23. pii: S2405-4569(18)30336-5. doi: 10.1016/j.euf.2018.11.004. [Epub ahead of print]

PMID:
30477971
25.

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.

Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

Int J Cancer. 2019 May 1;144(9):2303-2312. doi: 10.1002/ijc.32002. Epub 2019 Feb 4.

PMID:
30446996
26.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

27.

Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.

Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H.

Int J Cancer. 2019 Mar 1;144(5):1061-1072. doi: 10.1002/ijc.31939. Epub 2018 Dec 3.

PMID:
30350867
28.

Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.

Leichsenring J, Stögbauer F, Volckmar AL, Buchhalter I, Oliveira C, Kirchner M, Fröhling S, Hassel J, Enk A, Schirmacher P, Endris V, Penzel R, Stenzinger A.

Pathology. 2018 Dec;50(7):703-710. doi: 10.1016/j.pathol.2018.08.004. Epub 2018 Oct 20.

PMID:
30348504
29.

[Centralized molecular tumor diagnostics by commercial providers : Consequences for patients, patient care, and research].

Schirmacher P, Stenzinger A, Kirchner T.

Pathologe. 2018 Nov;39(6):583-586. doi: 10.1007/s00292-018-0523-x. German. No abstract available.

PMID:
30338351
30.

Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.

Bonekamp D, Schelb P, Wiesenfarth M, Kuder TA, Deister F, Stenzinger A, Nyarangi-Dix J, Röthke M, Hohenfellner M, Schlemmer HP, Radtke JP.

Eur Radiol. 2019 Apr;29(4):1820-1830. doi: 10.1007/s00330-018-5751-1. Epub 2018 Oct 16.

PMID:
30327861
31.

Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.

Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A.

Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30.

PMID:
30255938
32.

Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.

Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A.

Int J Cancer. 2019 Feb 15;144(4):848-858. doi: 10.1002/ijc.31878. Epub 2018 Dec 4.

PMID:
30238975
33.

Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.

Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A.

Genes Chromosomes Cancer. 2019 Jan;58(1):3-11. doi: 10.1002/gcc.22682. Epub 2018 Oct 17.

PMID:
30230086
34.

Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800034. doi: 10.1002/prca.201800034. Epub 2018 Oct 15.

PMID:
30216696
35.

Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.

Treue D, Bockmayr M, Stenzinger A, Heim D, Hester S, Klauschen F.

Int J Cancer. 2019 Feb 1;144(3):545-557. doi: 10.1002/ijc.31845. Epub 2018 Nov 8.

PMID:
30183078
36.

Prostatic metastasis from intrahepatic cholangiocarcinoma.

Tosev G, Schuetz V, Nyarangi-Dix J, Stenzinger A, Stoegbauer F, Kulu Y, Radtke JP, Teber D, Hatzinger M, Springfeld C, Koehler BC, Hohenfellner M.

Urol Case Rep. 2018 Jul 18;20:90-91. doi: 10.1016/j.eucr.2018.07.015. eCollection 2018 Sep. No abstract available.

37.

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.

Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800035. doi: 10.1002/prca.201800035. Epub 2018 Aug 21.

PMID:
30035857
38.

EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.

Christopoulos P, Kirchner M, Endris V, Stenzinger A, Thomas M.

J Thorac Dis. 2018 Jun;10(Suppl 17):S1989-S1991. doi: 10.21037/jtd.2018.05.61. No abstract available.

39.

Molecular dissection of large cell carcinomas of the lung with null immunophenotype.

Harms A, Endris V, Winter H, Kriegsmann M, Stenzinger A, Schirmacher P, Warth A, Kazdal D.

Pathology. 2018 Aug;50(5):530-535. doi: 10.1016/j.pathol.2018.03.005. Epub 2018 Jun 27.

PMID:
29958730
40.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A.

J Natl Compr Canc Netw. 2018 Jun;16(6):677-682. doi: 10.6004/jnccn.2018.7012.

PMID:
29891518
41.

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25.

PMID:
29802158
42.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

43.

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data.

Budczies J, Pfarr N, Romanovsky E, Endris V, Stenzinger A, Denkert C.

BMC Bioinformatics. 2018 Apr 24;19(1):157. doi: 10.1186/s12859-018-2159-5.

44.

Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.

Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T.

Eur J Haematol. 2018 Jul;101(1):115-118. doi: 10.1111/ejh.13072. Epub 2018 May 11.

PMID:
29624748
45.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Nov;59(11):2660-2669. doi: 10.1080/10428194.2018.1443450. Epub 2018 Apr 4.

PMID:
29616856
46.

Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.

Kriegsmann M, Harms A, Kazdal D, Fischer S, Stenzinger A, Leichsenring J, Penzel R, Longuespée R, Kriegsmann K, Muley T, Safi S, Warth A.

Pathol Res Pract. 2018 Mar;214(3):408-416. doi: 10.1016/j.prp.2017.12.018. Epub 2018 Jan 2.

PMID:
29487011
47.

Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.

Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, Stenzinger A, Burn J, von Knebel Doeberitz M, Bläker H, Kloor M.

Int J Cancer. 2018 Jul 1;143(1):139-150. doi: 10.1002/ijc.31300. Epub 2018 Feb 23.

48.

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M.

Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24.

49.

Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix.

Jesinghaus M, Konukiewitz B, Foersch S, Stenzinger A, Steiger K, Muckenhuber A, Groß C, Mollenhauer M, Roth W, Detlefsen S, Weichert W, Klöppel G, Pfarr N, Schlitter AM.

Mod Pathol. 2018 May;31(5):829-839. doi: 10.1038/modpathol.2017.184. Epub 2018 Jan 12.

50.

Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S.

Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0.

Supplemental Content

Loading ...
Support Center